Quantum Pharma completes Mucodis range with vaginal cream

Niche pharmaceutical developer Quantum Pharma announced on Friday that its subsidiary Colonis has launched Mucodis vaginal cream.

The AIM-traded company said the cream is part of the Mucodis range of in-licensed patented medical devices, which focus on treating some of the side effects experienced by patients undergoing the treatment of cancer.

It said Mucodis vaginal cream aids the treatment of painful symptoms induced by radiation vaginitis or vulvovaginitis due to radiotherapy and chemotherapy treatment of pelvic tumours.

Of the 172,000 women who are diagnosed with cancer each year, 20% will have cancers of the lower abdomen or pelvis, according to Quantum’s board.

It said the wider Mucodis range provides the NHS with prescribable products to address a number of the side effects associated with cancer treatments including mucositis, radiation-induced dermatitis, vulvovaginitis and proctitis.

Colonis has been granted an exclusive distribution licence for these products for five years, with an option to extend beyond this initial period.

“We are pleased to launch the Mucodis vaginal cream to help treat the unpleasant and painful side effects of cancer treatment,” said acting chief executive Chris Rigg.

“This completes the initial range of our Mucodis branded range of unique, cost effective and patented range of medical devices for the treatment of some of the side effects of oncology treatment.

“The cost to the NHS is highly competitive versus other products in this area,” Rigg explained.

He said that while it is still relatively early following the launch of the range, and as such Quantum is still in the market access phase, the initial response from clinical teams at hospitals has been “encouraging”.

“We are positive on the outlook for the range over the short to medium term.”